Core Viewpoint - Fortrea Holdings, Inc. is facing a securities class action lawsuit due to allegations of misleading investors regarding its financial projections and business model viability during the class period from July 3, 2023, to February 28, 2025 [3]. Group 1 - The lawsuit claims that Fortrea overstated projected revenue from Pre-Spin Projects, exaggerated expected cost savings from exiting transition service agreements, and inflated EBITDA targets for 2025 [3]. - Investors are reminded of the August 1, 2025 deadline to seek appointment as lead plaintiff in the class action lawsuit [1][4]. - Wolf Haldenstein Adler Freeman & Herz LLP, the law firm handling the case, has over 125 years of experience in securities litigation and aims to protect the rights of investors [4].

NEW YORK, June 27, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Fortrea Holdings Inc. ("Fortrea Holdings Inc." or the "Company") (NASDAQ: FTRE) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Fortrea Holdings Inc. investors who were adversely affected by alleged securities fraud between July 3, 2023 and February 28, 2025. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/f ...

NEW YORK, June 26, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Fortrea Holdings Inc. (NASDAQ: FTRE). Shareholders who purchased shares of FTRE during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/fortrea-holdings-inc-loss-submission-form/?id=154294&from=3 CLASS PERIOD: Ju ...

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Fortrea Holdings Inc. regarding a class action lawsuit alleging that the company made materially false and misleading statements during the class period from July 3, 2023, to February 28, 2025 [1][2]. Allegations - The complaint claims that Fortrea overestimated the revenue contributions from its long-term projects, known as the Pre-Spin Projects, to the company's 2025 earnings [1]. - It is alleged that Fortrea overstated the cost savings expected from exiting transition services agreements [1]. - The company's previously announced EBITDA targets for 2025 were inflated as a result of these misstatements [1]. - The viability of Fortrea's post-spin-off business model and its financial prospects were also overstated [1]. - Consequently, the company's public statements were materially false and misleading throughout the relevant period [1]. Next Steps for Shareholders - Shareholders who purchased FTRE shares during the specified class period are encouraged to register for the class action by August 1, 2025, to potentially be appointed as lead plaintiff [2]. - Registered shareholders will receive status updates through a portfolio monitoring software during the lifecycle of the case [2]. About the Gross Law Firm - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting the rights of investors affected by deceit and illegal business practices [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements or omissions [3].

Core Viewpoint - A lawsuit has been filed against Fortrea Holdings Inc. and its senior executives for potential violations of federal securities laws, stemming from allegations of overstating cost savings and revenue projections related to transition services agreements following its spin-off from Labcorp [1][2][4]. Group 1: Company Background - Fortrea Holdings Inc. is a global contract research organization that provides biopharmaceutical product and medical device development solutions [3]. - The company was spun off from Labcorp Holdings Inc. in June 2023, becoming a standalone publicly traded entity [3]. Group 2: Allegations and Financial Impact - The lawsuit claims that Fortrea exaggerated the cost savings and margin improvements expected from exiting transition services agreements with Labcorp [4]. - Following a report from Jefferies on September 25, 2024, which indicated that the anticipated cost savings were not as significant as previously thought, Fortrea's stock price fell by $2.73, or over 12%, from $22.21 to $19.48 per share [5]. - On March 3, 2025, Fortrea announced disappointing financial results for Q4 and full year 2024, revealing lower-than-expected revenue and profitability from pre-spin projects, leading to a further decline in stock price by $3.47, or over 25%, from $13.85 to $10.38 per share [6].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Fortrea Holdings, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline on August 1, 2025, and the potential for compensation without out-of-pocket costs [1][2] Group 1: Class Action Details - The class action lawsuit against Fortrea Holdings alleges that the company made false and misleading statements regarding its revenue projections and cost savings, leading to inflated EBITDA targets for 2025 [4] - Investors who purchased Fortrea securities between July 3, 2023, and February 28, 2025, may be eligible for compensation [1][4] - A lead plaintiff must file a motion with the court by August 1, 2025, to represent other class members in the litigation [2] Group 2: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [3] - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [3] - Founding partner Laurence Rosen was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020, highlighting the firm's expertise in this area [3]

Core Viewpoint - Fortrea Holdings Inc. is facing a class action securities lawsuit due to alleged securities fraud that affected investors between July 3, 2023, and February 28, 2025 [1][2]. Group 1: Allegations and Impact - The lawsuit claims that Fortrea Holdings Inc. overestimated revenue contributions from its long-term projects, known as the Pre-Spin Projects, for the year 2025 [2]. - It is alleged that the company overstated potential cost savings from exiting transition services agreements, leading to inflated EBITDA targets for 2025 [2]. - The viability of Fortrea's post-spin-off business model and its financial prospects were reportedly overstated, resulting in materially false and misleading public statements [2]. Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until August 1, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require this role [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, with no obligation to participate [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [4]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [4].

Core Viewpoint - Fortrea Holdings Inc. is facing a federal securities class action lawsuit due to allegations of misleading statements regarding its financial performance and business model, particularly concerning its revenue projections and cost savings [5][3]. Group 1: Legal Investigation and Class Action - Faruqi & Faruqi, LLP is investigating potential claims against Fortrea and has set an August 1, 2025 deadline for investors to seek the role of lead plaintiff in the class action [3]. - Investors who suffered losses exceeding $50,000 in Fortrea between July 3, 2023, and February 28, 2025, are encouraged to contact the firm for legal options [1]. Group 2: Allegations Against Fortrea - The complaint alleges that Fortrea overestimated revenue contributions from Pre-Spin Projects and overstated cost savings from exiting Transition Service Agreements (TSAs), leading to inflated EBITDA targets for 2025 [5]. - The company's public statements regarding its business model and financial prospects were deemed materially false and misleading [5]. Group 3: Stock Performance and Analyst Downgrades - On September 25, 2024, Jefferies downgraded Fortrea from buy to hold, citing weaknesses in its business model and a decline in stock price by $2.73 (12.29%) to $19.48 [6]. - Following the cancellation of two scheduled conferences, Baird Equity Research downgraded Fortrea to neutral on December 6, 2024, resulting in a stock price drop of $1.90 (8.06%) to $21.67 [7]. - Fortrea's fourth quarter and full year 2024 results revealed that its revenue and adjusted EBITDA expectations for 2025 were not aligned with prior forecasts, causing a significant stock price decline of $3.47 (25.05%) to $10.38 on March 3, 2025 [8].

Core Insights - Fortrea has established a strategic partnership with Emery Pharma to support the detection of nitrosamine impurities, specifically 1-methyl-4-nitrosopiperazine (MNP), in the drug rifampicin for drug-drug interaction (DDI) studies [1][2] - The collaboration aims to ensure that impurity levels remain below the acceptable intake limits set by the FDA, thereby enhancing the safety and efficacy of clinical trials [1][2] Group 1: Partnership Details - Fortrea selected Emery Pharma due to its strong capabilities in analytical and bioanalytical testing, which will support Fortrea's global clinical projects [2] - The partnership allows sponsors to utilize rifampicin for DDI assessments, leveraging its excellent safety and tolerability profile [2] - The collaboration is expected to reduce early trial risks, accelerate trial timelines, and improve data quality [2] Group 2: Impurity Detection and Regulatory Compliance - The new impurity detection level for rifampicin is now available for Fortrea's clients conducting clinical pharmacology trials, designed to be flexible and compliant with FDA requirements [3] - The FDA previously identified that all tested batches of rifampicin exceeded acceptable MNP levels, prompting researchers to seek alternative drugs, which posed safety risks [2] - In 2023, the FDA updated guidelines, raising the acceptable limits for MNP in rifampicin [2] Group 3: Company Backgrounds - Fortrea is a leading global clinical development solutions provider, collaborating with biopharmaceutical, biotechnology, medical device, and diagnostic companies to expedite medical innovations [4] - Emery Pharma is recognized for its scientific leadership in impurity analysis and regulatory compliance, focusing on GLP and cGMP analytical testing [5][6] - Emery Pharma specializes in developing and validating sensitive and specific analytical methods for nitrosamine detection, playing a crucial role in helping pharmaceutical sponsors navigate evolving FDA and ICH guidelines [5][6]

Core Viewpoint - A lawsuit has been filed against Fortrea Holdings Inc. and its senior executives for potential violations of federal securities laws, following allegations of overstating cost savings and revenue projections related to transition services agreements after its spin-off from Labcorp [1][2][4]. Group 1: Company Background - Fortrea Holdings Inc. is a global contract research organization that provides biopharmaceutical product and medical device development solutions. It was spun off from Labcorp Holdings Inc. in June 2023 [3]. Group 2: Allegations and Financial Impact - The lawsuit claims that Fortrea exaggerated the cost savings and margin improvements expected from exiting transition services agreements with Labcorp, as well as the revenue from pre-spin projects [4]. - Following a report from Jefferies on September 25, 2024, which indicated that the anticipated cost savings were not as significant as previously thought, Fortrea's stock price fell by $2.73, or over 12%, from $22.21 to $19.48 per share [5]. - On March 3, 2025, Fortrea announced disappointing Q4 and full-year 2024 financial results, revealing lower-than-expected revenue and profitability from pre-spin projects, leading to a further decline in stock price by $3.47, or over 25%, from $13.85 to $10.38 per share [6].